Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX((R)) criteria

Olivier Bruyere*, M. Fossi, B. Zegels, L. Leonori, M. Hiligsmann, A. Neuprez, J.Y. Reginster

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)973-978
JournalRheumatology International
Volume33
Issue number4
DOIs
Publication statusPublished - Apr 2013

Keywords

  • FRAX
  • Osteoporosis
  • Drug
  • Economic evaluation
  • Reimbursement

Cite this